Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case

Multiple Sclerosis

Volumn 22, Issue 12, 2016, Pages 1541-1549

  Jarius, Sven ^a   Metz, Imke ^b   König, Fatima Barbara ^b   Ruprecht, Klemens ^c   Reindl, Markus ^d   Paul, Friedemann ^e   Brück, Wolfgang ^a   Wildemann, Brigitte ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e Experimental and Clinical Research Center   (Germany)

Author keywords

aquaporin 4; autoantibodies; biopsy; complement; contactin associated protein 2; dipeptidyl peptidase like protein 6; glioma activated protein 1; histopathology; leucine rich; metabotropic gamma aminobutyric acid receptors; Multiple sclerosis; myelin oligodendrocyte glycoprotein; N methyl d aspartate type glutamate receptors; neuropathology; pattern II; voltage gated potassium channels; amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid receptor type glutamate receptors

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR ANTIBODY; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID RECEPTOR TYPE GLUTAMATE RECEPTOR ANTIBODY; AMPHIPHYSIN ANTIBODY; ANTIBODY; AUTOANTIBODY; CARBONIC ANHYDRASE RELATED PROTEN ANTIBODY; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5 ANTIBODY; CONTACTIN ASSOCIATED PROTEIN 2 ANTIBODY; DELTA NOTCH LIKE EPIDERMAL GROWTH FACTOR RELATED RECEPTOR ANTIBODY; DIPEPTIDYL PEPTIDASE LIKE PROTEIN 6 ANTIBODY; GLIOMA ACTIVATED PROTEIN ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; HOMER3 ANTIBODY; HU ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR 1 ANTIBODY; LEUCINE RICH ANTIBODY; M1 AQUAPORIN 4 ANTIBODY; M23 AQUAPORIN 4 ANTIBODY; MA1 ANTIBODY; MA2 ANTIBODY; METABOTROPIC GLUTAMATE RECEPTOR 1 ANTIBODY; METABOTROPIC GLUTAMATE RECEPTOR 5 ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; PROTEIN KINASE GAMMA ANTIBODY; RHOGTPASE ACTIVATING PROTEIN 26 ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; YO ANTIBODY; NERVE PROTEIN;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; BRAIN BIOPSY; BRAIN DAMAGE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATTERN II MULTIPLE SCLEROSIS; BIOPSY; BLOOD; BRAIN; CASE REPORT; COMPLEMENT ACTIVATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY;

AUTOANTIBODIES; BIOPSY; BRAIN; COMPLEMENT ACTIVATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NERVE TISSUE PROTEINS;

EID: 84991373145     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515622986     Document Type: Article

References (37)

1. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
2. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366: 579-582.
3. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012; 9: 14.
4. Reindl M, Di Pauli F, Rostasy K, et al. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013; 9: 455-461.
5. Jarius S, Wildemann B, Paul F,. Neuromyelitis optica: Clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014; 176: 149-164.
6. Levy M, Wildemann B, Jarius S, et al. Immunopathogenesis of neuromyelitis optica. Adv Immunol 2014; 121: 213-242.
7. Bruck W, Popescu B, Lucchinetti CF, et al. Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol 2012; 72: 385-394.
8. Kuhlmann T, Lassmann H, Bruck W,. Diagnosis of inflammatory demyelination in biopsy specimens: A practical approach. Acta Neuropathol 2008; 115: 275-287.
9. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8: 184.
10. Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 75: 411-428.
11. Saadoun S, Waters P, Owens GP, et al. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2014; 2: 35.
12. Balint B, Jarius S, Nagel S, et al. Progressive encephalomyelitis with rigidity and myoclonus: A new variant with DPPX antibodies. Neurology 2014; 82: 1521-1528.
13. Stoeck K, Carstens PO, Jarius S, et al. Prednisolone and azathioprine are effective in DPPX antibody-positive autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2015; 2: e86.
14. Jarius S, Wildemann B,. 'Medusa head ataxia': The expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation 2015; 12: 168.
15. Probst C, Komorowski L, de Graaff E, et al. Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm 2015; 2: e68.
16. Jarius S, Wandinger KP, Horn S, et al. A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: Immunological characterization. J Neuroinflammation 2010; 7: 21.
17. Jarius S, Martinez-Garcia P, Hernandez AL, et al. Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. J Neuroinflammation 2013; 10: 7.
18. Jarius S, Wildemann B,. 'Medusa head ataxia': The expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC. J Neuroinflammation 2015; 12: 167.
19. Doss S, Nümann A, Ziegler A, et al. Anti-Ca/anti-ARHGAP26 antibodies associated with cerebellar atrophy and cognitive decline. J Neuroimmunol 2014; 267: 102-104.
20. Jarius S, Scharf M, Begemann N, et al. Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia. J Neuroinflammation 2014; 11: 206.
21. Jarius S, Wildemann B,. 'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. J Neuroinflammation 2015; 12: 166.
22. Jarius S, Probst C, Borowski K, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010; 291: 52-56.
23. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68: 1076-1077.
24. Jarius S, Franciotta D, Paul F, et al. Testing for antibodies to human aquaporin-4 by ELISA: Sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci 2012; 320: 32-37.
25. Jarius S, Paul F, Franciotta D, et al. Mechanisms of Disease: Aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008; 4: 202-214.
26. Jarius S, Wildemann B,. AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6: 383-392.
27. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450-1461.
28. Genain CP, Cannella B, Hauser SL, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 170-175.
29. Zamvil SS, Slavin AJ,. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015; 2: e62.
30. Kale N, Pittock SJ, Lennon VA, et al. Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgG. Arch Neurol 2009; 66: 1298-1299.
31. Jarius S, Wildemann B,. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: A critical review of the literature. Brain Pathol 2013; 23: 661-683.
32. Konig FB, Wildemann B, Nessler S, et al. Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol 2008; 65: 1527-1532.
33. Spadaro M, Gerdes LA, Mayer MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2015; 2: 295-301.
34. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008; 65: 913-919.
35. Jarius S, Wandinger KP, Borowski K, et al. Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: Case report and review of the literature. Clin Neurol Neurosurg 2012; 114: 331-335.
36. Mayer MC, Breithaupt C, Reindl M, et al. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 2013; 191: 3594-3604.
37. Jarius S, Paul F, Fechner K, et al. Aquaporin-4 antibody testing: Direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation 2014; 11: 129.